AI Summary

A study led by the University of Birmingham and Nonacus Ltd. evaluated the GALEAS™ Bladder urine test in 964 patients referred urgently for suspected bladder cancer across seven NHS urology departments. The commercially available test, which analyzes genomic markers in urine, identified 71 of 77 cancers, a detection rate of 92.2%. The findings, published in European Urology Oncology, demonstrate the test’s effectiveness as a noninvasive screening tool for bladder cancer in a real‑world clinical setting.

AI summaries can be wrong sometimes—always verify important details using the source article.